ANTIPHOSPHOLIPID SYNDROME (APS)
Clinical trials for ANTIPHOSPHOLIPID SYNDROME (APS) explained in plain language.
Never miss a new study
Get alerted when new ANTIPHOSPHOLIPID SYNDROME (APS) trials appear
Sign up with your email to follow new studies for ANTIPHOSPHOLIPID SYNDROME (APS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cell therapy tested for patients with untreatable autoimmune diseases
Disease control Recruiting nowThis is an early-stage study to check the safety of a new cell therapy called YTS109 for adults with severe autoimmune diseases that have not responded to standard treatments. About 18 participants with conditions like lupus, scleroderma, or vasculitis will receive a single infus…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Real-World test: can newer blood thinners safely prevent clots in autoimmune patients?
Disease control Recruiting nowThis study aims to see if newer, easier-to-use blood thinners (DOACs) work as well and are as safe as the older standard medication (warfarin) for preventing repeat blood clots. It will follow 600 adults with a specific autoimmune clotting disorder who have already had a clot and…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Sponsor: Infanta Leonor University Hospital • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New cell therapy tested for Hard-to-Treat autoimmune conditions
Disease control Recruiting nowThis is an early-stage study to check the safety of a new cell therapy called YTS109 in adults with severe autoimmune diseases that have not improved with standard treatments. About 18 participants with conditions like lupus, Sjogren's syndrome, or vasculitis will receive a singl…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Doctors track blood clot patients to update outdated risk data
Knowledge-focused Recruiting nowThis study aims to better understand how often dangerous blood clots return in people with antiphospholipid syndrome, a rare autoimmune condition. Researchers will follow 200 patients over time to track their health outcomes and identify factors that increase recurrence risk. The…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC